27 results about "Organ preservation solution" patented technology

The invention relates to the technical field of organ transplantation, and discloses organ preserving fluid, application and organ dynamic supercooling perfusion equipment. The organ preserving fluid is prepared from ribose, glucose, mannitol, lidocaine, adenosine, a high-molecular polymer, L-proline, trehalose, inorganic salt and organic salt. The high-molecular polymer comprises one of hydroxyethyl starch, polyethylene glycol and albumin. According to the organ preserving fluid disclosed by the invention, the freezing point of the perfusate is reduced through the micromolecular cryoprotectant, and meanwhile, the micromolecular cryoprotectant and the high-molecular polymer jointly inhibit formation and growth of ice crystals; the problem of liquid preservation at the temperature below zero is solved from the two dimensions of physics (reducing the freezing point and inhibiting ice crystals) and biology (maintaining cell viability), and feasibility is provided for long-time low-temperature transfer and transplantation of organs. The preserving fluid can be used for static preservation or perfusion preservation of various organs such as kidney, liver, heart, pancreas, lung, small intestine, skin and the like.

The application discloses a kind of pharmaceutical composition, organ preservation fluid and its application, the pharmaceutical composition includes seduxian and edaravone.The mass ratio of seduxian and edaravone is 1:0.0001-10000.The cell protection effect of the pharmaceutical composition of the application is good, seduxian and edaravone show synergistic effect, help to obtain excellent curative effect, and reduce drug dosage, help to improve clinical drug safety.

Serum albumin is an important molecule in human and animal blood. It provides oncotic pressure and acts as a transportation agent, delivering nutrients from the blood to the tissue and removing waste products from the tissue to the blood. This invention describes an organ preservation and / or perfusion solution which comprises acetylated serum albumin, as well as method of making and using such a solution, and uses of acetylated serum albumin itself. The acetylated serum albumin utilised in the present invention can protect the vascular endothelium during perfusion of an isolated organ or tissue.

A pharmaceutical composition, an organ preservation solution, and their applications are disclosed, wherein the pharmaceutical composition comprises cedutinib and edaravone. The mass ratio of cedutinib to edaravone is 1:0.0001-10000. The pharmaceutical composition of the present invention exhibits good cell protection effects, and cedutinib and edaravone demonstrate a synergistic effect, contributing to excellent therapeutic efficacy, reducing drug dosage, and improving clinical drug safety.

Disclosed herein are methods and compositions for preserving or conditioning organs prior to transplantation. Compositions of the invention comprise plasmin and / or a functionally active mutant thereof formulated in a pharmaceutically acceptable organ preservation solution. The composition is stable and non-toxic to organs intended for transplantation.

The invention belongs to the technical field of medical equipment, and particularly discloses a reversible electroporation combined medical kit for organ transplantation and transfer and application of the reversible electroporation combined medical kit. According to the medical kit for organ transplantation, a novel electric pulse device is additionally designed on the basis of original design, a large amount of emergency response generated after organ transplantation can be remarkably reduced, and the survival rate of organs is increased. The novel electric pulse device is designed to be attached to the inner wall of the box body, the designed electric pulse electrode plate is attached to the buffer pad, the buffer pad is made of an insulating non-toxic heat preservation material, and organ preservation liquid is contained in the organ preservation bag. According to the medical kit for organ transplantation, the additional electrodes can be used for applying electric pulses to organs in the organ storage bag, medicine in the organ storage liquid is promoted to enter the organs, meanwhile, the optimal applied pulse intensity is confirmed in combination with cell experiments, the potential distribution condition is simulated and confirmed in combination with simulation software, and emergency reaction generated after perfusion can be reduced; therefore, normal organ functions are ensured, and the success rate of transplantation is improved.

The invention relates to a pharmaceutical composition, an organ preserving fluid and an application of the organ preserving fluid. The pharmaceutical composition comprises telaprevir and borneol. The mass ratio of the telaprevir to the borneol is 1: (0.0001-1000). The pharmaceutical composition disclosed by the invention is good in cell protection effect, telaprevir and borneol show a synergistic effect, excellent curative effects are favorably obtained, the dosage of the medicine is reduced, and the clinical medication safety is favorably improved.

An oxygenation apparatus (10) for producing an organ preservation solution (56') comprising nanobubbles of gas including oxygen, includes a flow path for passage of a precursor organ preservation solution and a nanoporous gas diffuser (12). The flow path for passage of a precursor organ preservation solution (56) comprises at least one constricted portion followed by one or more expanded portion. The nanoporous gas diffuser (12) is adapted for connection to a source of gas including oxygen (32) and disposed for fluid contact with the precursor organ preservation solution (56) passing through the flow path. An organ preservation apparatus comprising an oxygenation apparatus is also provided. Methods of use of said apparatus in organ preservation are also provided.

The present application relates to a kind of pharmaceutical composition, organ preservation fluid and its application, the pharmaceutical composition includes terapib and camphor.The mass ratio of terapib and camphor is 1:0.0001-1000.The cell protection effect of the pharmaceutical composition of the present application is good, terapib and camphor show synergistic effect, help to obtain excellent curative effect, and reduce the drug dosage, help to improve clinical drug safety.

The invention discloses a pharmaceutical composition, an organ preserving fluid and application of the organ preserving fluid. The pharmaceutical composition comprises Ceridutinib and edaravone. The mass ratio of the tidutinib to the edaravone is 1: (0.0001-10000). The pharmaceutical composition disclosed by the invention has a good cell protection effect, and the cedutinib and the edaravone show a synergistic effect, so that an excellent curative effect can be obtained, the dosage of the medicine can be reduced, and the clinical medication safety can be improved.

The utility model discloses an automatic organ preserving fluid adding and transferring device, which relates to the technical field of living tissue transportation and comprises a storage cylinder, a cylinder cover is movably mounted on the outer side of the storage cylinder close to the upper side, and the upper side of the cylinder cover is fixedly connected with a fluid storage bin. Handles are fixedly connected to the positions, close to the upper side, of the left side and the right side of the storage barrel, the inner side of the storage barrel is movably sleeved with a placement mechanism, and a liquid injection mechanism is rotationally connected to the upper side of the placement mechanism. According to the automatic organ preserving fluid adding and transferring device, through pulling of the tension spring, the pressing plate is used for fastening the tank cover, the injection pipe is pushed through the electric push rod, the pressing net is made to move up and down, the height of the pressing net can be adjusted, small biological tissue is prevented from shaking at will when transported in the inner tank, and the working efficiency is improved. Meanwhile, when the whole bottom plate is placed, the tank cover is still in a fixed state, and the living tissue is prevented from spilling out.

The invention relates to the technical field of organ transplantation, and provides organ dynamic supercooling perfusion equipment which comprises a liquid storage assembly, a power assembly, a temperature control assembly and an organ storage assembly, the liquid storage assembly provides organ preservation liquid, and the organ preservation liquid is in a liquid state at the temperature below 4 DEG C; the power assembly is connected to the liquid outlet of the liquid storage assembly, and the power assembly is used for driving the organ preservation liquid to flow; the temperature control assembly is connected to a liquid outlet of the power assembly, and the temperature control assembly is used for adjusting the temperature of the organ preservation liquid; a liquid inlet intubation tube of the organ storage assembly is connected to a liquid outlet of the temperature control assembly, a liquid outlet intubation tube of the organ storage assembly is connected with a liquid inlet of the liquid storage assembly, and the organ storage assembly is used for containing organs and conducting supercooling perfusion on the organs through the liquid inlet intubation tube and the liquid outlet intubation tube. According to the perfusion equipment provided by the invention, through the cooperation of the specific organ preserving fluid and the dynamic perfusion of the equipment assembly, the dynamic perfusion can be realized in a subzero temperature zone without freezing risk, and the dynamic supercooling is carried out on the organ from inside to outside.

The invention provides an organ preservation (Multiplex-Saccharide, MS) solution composed of polysaccharide substances, and an application of the organ preservation (Multiplex-Saccharide, MS) solution composed of polysaccharide substances and the application of the organ preservation (Multiplex-Saccharide, MS) solution. The preservation liquid is suitable for cold preservation of isolated organs, and belongs to the field of abdominal organ function preservation liquid. The preserving fluid mainly comprises the following components in concentration: hydroxyethyl starch (MW130000), cane sugar, sodium gluconate, sulfate, phosphate solution and the like which are added into 1000mL of aqueous solution. The preserving fluid has the effect of cold preservation (0-4 DEG C) for cells and tissues, especially for abdominal visceral organs. Research data show that the preserving fluid has recovery activity after kidney cold preservation for 18 hours and organ reperfusion, and compared with a standard organ preserving fluid UW fluid used clinically at present, organ function recovery after organ transplantation is faster. The MS organ preserving fluid is expected to replace imported organ preserving fluid, provides better protection for donor preservation of clinical organ transplantation, and has broad clinical application prospects.

The invention belongs to the technical field of biomedical materials, and particularly relates to a novel organ cryopreservation solution based on PVP (Polyvinyl Pyrrolidone) and containing fluorocarbon emulsion. The invention discloses an organ preserving fluid which takes KPS-1 as a basis, polyvinylpyrrolidone (PVP) as a main anti-freezing component, fluorocarbon emulsion as an oxygen carrying agent and ATP and glucose as energy donors. In addition, the cleaning agent contains the surfactant, trehalose and other components, does not contain DMSO, and is non-toxic. Compared with the traditional UW liquid which can be preserved for 24 hours at 4 DEG C, the oxygen carrying capacity is remarkably improved, ischemia reperfusion injury is reduced, the UW liquid can be preserved for a long time at the ultralow temperature of-80 DEG C, and meanwhile sufficient energy is provided for maintaining metabolism of isolated organs. The cryopreservation time of tissues and organs such as in-vitro liver and kidney can be remarkably prolonged, and the preservation effect is superior to that of UW liquid.

Disclosed herein are methods and compositions for preserving or reconditioning organs prior to transplantation. The compositions of the invention contain plasmin and / or functionally active variants thereof formulated in a pharmaceutically acceptable organ preservation solution. The compositions of the invention are stable and non-toxic to organs intended for transplantation.

Provided are a pharmaceutical composition, an organ preservation solution, and use thereof. The pharmaceutical composition comprises cerdulatinib and edaravone. The mass ratio of cerdulatinib to edaravone is 1: 0.0001-10000. The pharmaceutical composition of the present invention has a good protection effect on cells; cerdulatinib and edaravone exhibit a synergistic effect, an excellent therapeutic effect with a reduced dose, and improved clinical administration safety.

The application discloses an anti-free radical polymer capable of reducing organ ischemia-reperfusion injury, a preparation method and application thereof, and a structural formula is shown as follows: wherein x represents a proportion of a tetramethylpiperidine modification part in the polymer, x is 0.01-0.3; n represents a chain number of the polymer, n is 10-100, and R is selected from one of a methyl group, an ethyl group, a normal propyl group, an isopropyl group and a normal butyl group. The application can target mitochondria, has a function of combining free radicals, has an obvious effect of reducing liver ischemia-reperfusion injury, and has an effect of reducing cold ischemia injury of the liver when being added into an organ preservation solution.

The invention discloses a pharmaceutical composition for targeted activation of FSP1 and application of the pharmaceutical composition. The pharmaceutical composition comprises a medicine capable of activating ferroptosis inhibitory protein 1 and a reduced coenzyme I capable of enhancing the ferroptosis inhibitory protein 1 activation effect of the medicine. The medicine capable of activating the ferroptosis inhibition protein 1 comprises a second-generation sulfonylurea medicine; and the second generation sulfonylurea medicine is glimepiride or glibenclamide. The glimepiride, glibenclamide and other second-generation sulfonylurea drugs are combined with NADH, and the resistance of cells to ferroptosis can be remarkably improved by activating or improving the activity of FSP1, so that cell death after ischemia-reperfusion injury is inhibited; meanwhile, the invention provides new application of the glimepiride, the glibenclamide and other hypoglycemic drugs, the adaptation diseases of the glimepiride, the glibenclamide and other hypoglycemic drugs are expanded, and the glimepiride, the glibenclamide and other hypoglycemic drugs are combined with the NADH, so that the glimepiride, the glibenclamide and other hypoglycemic drugs can be used for treating ischemia reperfusion injury related diseases and organ preservation liquid to improve the protection effect on organs.

The invention relates to the technical field of organ transplantation, in particular to organ preserving fluid as well as a preparation method and application thereof. The organ preserving fluid comprises the following components: histidine; n, N-acetyl histidine monohydrate; vitamin C magnesium stearate; tryptophan; and alpha-ketoglutaric acid; trehalose; sodium chloride; potassium chloride; magnesium chloride * 6H2O; calcium chloride * 2H2O; aspartic acid; l-arginine is selected from L-arginine; glycine; l, L-alanine; eDTA (ethylene diamine tetraacetic acid); in addition, the composition also comprises rosmarinic acid and naringenin. The organ preserving fluid provided by the invention has better oxidation resistance.

The present invention discloses an improved method for kidney preservation solution, belonging to the technical field of organ preservation solutions. The method comprises adding a ganoderma lucidum extract and an epimedium extract to HC-A solution. The ganoderma lucidum extract contains ganoderma lucidum polysaccharides and total ganoderma lucidum triterpenes, while the epimedium extract contains icariin and epimedin. The improved method of the present invention, which adds the ganoderma lucidum extract and the epimedium extract to the HC-A solution, can reduce ischemic damage during cryopreservation of isolated kidneys by protecting mitochondrial structure, increasing calpain activity, and inhibiting cell apoptosis, oxidative stress, and inflammatory reactions. This method improves the preservation effect of HC-A solution for isolated kidneys, prolongs their preservation time, and thus increases the survival rate of kidney transplantation. This method provides a clinical approach to finding a safe and effective method for preserving donor kidneys.

An improved aqueous organ preservation solution is provided, which comprises taurine and L-alanine-L-glutamine and glutamic acid. It was found that the combination of these compounds can advantageously be used in such compositions. The or - gan preservation composition can be stored in a solid state, for example in the form of small particles (e.g. a powder or micronized powder), and be dissolved in water, thereby instantly providing a ready- to-use organ preservation solution.

The invention discloses application of a magnetic field generating device capable of conveniently protecting an organ function in assisting in low-temperature keep-alive of an in-vitro liver, and belongs to the technical field of in-vitro organ preservation and magnetic field application. The magnetic field generating device is a square magnet made of neodymium iron boron; the in-vitro liver is located above the magnetic field generating device, the magnetic field intensity of the square magnet is 50-400 mT, and the magnetic field direction is downward. The invention also provides a static cold preservation method of the in-vitro liver organ, which comprises the following steps: placing the liver soaked in the organ preservation liquid at different heights on the surface of the magnetic field generation device, and enabling the liver to be exposed under the magnetic field intensity of 50-400mT to be preserved for 12-48h. The magnetic field generating device has the beneficial effects that the magnetic field generating device has a good promoting effect on static cold preservation of liver organs, reduces oxidative stress of the liver and relieves an ion imbalance state, so that liver cell edema, apoptosis, mitochondrial damage and the like induced by static cold preservation are relieved, and the purposes of prolonging the preservation time and improving the preservation quality are achieved.

The invention discloses an organ storage solution and application thereof. The organ storage solution comprises Pan23 polypeptide and an organ preservation solution. The organ storage liquid provided by the invention can be used for reducing in-vitro injury of organs or tissues, reducing stress response of endoplasmic reticulum in cells, reducing formation of mitochondria-endoplasmic reticulum coupling bodies (MAMs), reducing formation of lipid droplets in the cells and cold injury of the cells, playing a role in protecting the mitochondria, improving generation of antioxidant enzymes in the cells and playing a role in protecting the cells.

An oxygenation apparatus (10) for producing an organ preservation solution (56') comprising nanobubbles of gas including oxygen, includes a flow path for passage of a precursor organ preservation solution and a nanoporous gas diffuser (12). The flow path for passage of a precursor organ preservation solution (56) comprises at least one constricted portion followed by one or more expanded portion. The nanoporous gas diffuser (12) is adapted for connection to a source of gas including oxygen (32) and disposed for fluid contact with the precursor organ preservation solution (56) passing through the flow path. An organ preservation apparatus comprising an oxygenation apparatus is also provided. Methods of use of said apparatus in organ preservation are also provided.

The present invention discloses a method for preparing a nanozyme and an anti-Klebsiella pneumoniae organ preservation solution composed of the nanozyme. The preparation method of the nanozyme comprises the following steps: S1, dispersing Ti3AlC2 powder in a mixed solution of LiF and HCl at a solid-liquid ratio of 1:20 (g / mL), and reacting at a constant temperature of 80°C for 36 hours to generate Ti3C2T x MXene precursor; S2, Ti3C2T x The MXene precursor was mixed with a plant polyphenol solution having a concentration of 0.5 g / L and a pH of 5.0, and subjected to a segmented ultrasonic power treatment for 4 h. The anti-Klebsiella pneumoniae organ preservation solution of the present invention was added with Ti3C2T x MXene nanozymes, due to Ti3C2T x The rich oxygen-containing functional groups on the surface of MXene nanozymes can interact with high-viscosity substances such as hydroxyethyl cellulose, successfully reducing viscosity and improving antioxidant effects, significantly prolonging the preservation time of mouse livers, and effectively inhibiting Klebsiella pneumoniae infection, providing better support for organ transplantation.

The application discloses a kind of for reducing transplantation fat liver ischemia-reperfusion injury preservation solution, belong to biomedical technical field.The application provides the application of fibroblast growth factor 21 in the preparation of drug or liver transplantation organ preservation solution for preventing and treating ischemia-reperfusion induced liver injury.By exogenous supplement fibroblast growth factor 21, ischemia-reperfusion induced hepatocyte injury can be effectively improved;Especially for fatty degeneration transplantation liver, not only can inhibit ischemia-reperfusion induced color tissue injury, apoptosis and inflammation, but also can improve intrahepatic lipid accumulation, reverse liver fatty degeneration, improve the efficacy of fatty degeneration donor liver transplantation.

Disclosed herein are methods and compositions for preserving or reconditioning organs prior to transplant. The compositions of the present invention contain plasmin and / or functionally active mutants thereof formulated in a pharmaceutically acceptable organ preservation solution. The compositions are stable and non-toxic to the organ intended for transplant.